The approval of potentially effective treatments for serious and life-threatening conditions represents a particularly difficult arena for drug developers, regulators and physicians. Hanging in the balance is the need to provide a timely treatment alternative to an otherwise untreatable and serious condition, while also assuring that the proposed treatment is sufficiently safe to preserve the overall wellbeing of the patient. This is a particularly difficult decision, as weighting the risk and benefits must be done fast and over a much finer scale than in situations where effective treatments are available.
2014-02-27 | 263 visitas | Evalua este artículo 0 valoraciones
Vol. 13 Núm.2. Marzo-Abril 2014 Pags. 163-165 Ann Hepatol 2014; 13(2)